BioCryst remains hopeful of FDA approval for its single-dose influenza drug despite mixed results

September 8, 2014 10:40 AM

2 0

BioCryst remains hopeful of FDA approval for its single-dose influenza drug despite mixed results

An experimental single-dose influenza drug has demonstrated mixed results in treating adult patients with flu when administered within 48 hours of the onset of symptoms, according to data due to be presented at the American Society of Microbiology’s annual ICAAC meeting in Washington, DC on 8 September 2014[1].

The drug, peramivir, developed by BioCryst Pharmaceuticals, failed to show significant symptom reduction when the data were adjusted for confounders but it reduced the time to resolution of fever by 24 hours, as well as reducing the amount of viral shedding in patients over the first two days.

Read more

To category page

Loading...